BioSpace News Archive

Algernon Pharmaceuticals Inc. is pleased to announce that it has engaged Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, and to assist in identifying and evaluating potential M&A and strategic opportunities, including the potential spin-off of the Company’s NP-120 (“Ifenprodil”) chronic cough research program.

BIOXYTRAN, INC. announced that the journal “ Vaccines ” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19.

Alcyone Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) to initiate a pivotal trial of Alcyone’s ThecaFlex DRx System (ThecaFlex).

Medical device company Linear Health Sciences today advanced the commercialization of its Orchid SRV ™ tension-activated breakaway safety release valve, announcing the appointment of Rob Headley as vice president of sales and business development, and Jessica Czamanski as director of product and regulatory affairs.

Anavex Life Sciences Corp. and Partex N.V. Group, the first Data-to-Drugs digital pharma platform, announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model.

Annovis Bio, Inc. announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition of matter provisional patent with the U.S. Patent and Trademark Office.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SOD1.

QurAlis Corporation and Unlearn today announced they have entered into a collaboration to accelerate and optimize QurAlis’ clinical program in ALS with Unlearn’s advanced generative artificial intelligence (AI) technology.

Predictive Oncology Inc. today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board.

Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent.